4 research outputs found
First Experience of Three Neurovascular Centers With the p64MW-HPC, a Low-Profile Flow Diverter Designed for Proximal Cerebral Vessels With Antithrombotic Coating
Background: In the last decade, flow diversion (FD) has been established as
hemodynamic treatment for cerebral aneurysms arising from proximal and distal cerebral
arteries. However, two significant limitations remain—the need for 0.027” microcatheters
required for delivery of most flow diverting stents (FDS), and long-term dual anti-platelet
therapy (DAPT) in order to prevent FDS-associated thromboembolism, at the cost
of increasing the risk for hemorrhage. This study reports the experience of three
neurovascular centers with the p64MW-HPC, a FDS with anti-thrombotic coating that
is implantable via a 0.021” microcatheter.
Materials and methods: Three neurovascular centers contributed to this retrospective
analysis of patients that had been treated with the p64MW-HPC between March 2020
and March 2021. Clinical data, aneurysm characteristics, and follow-up results, including
procedural and post-procedural complications, were recorded. The hemodynamic effect
was assessed using the O’Kelly–Marotta Scale (OKM).
Results: Thirty-two patients (22 female, mean age 57.1 years) with 33 aneurysms
(27 anterior circulation and six posterior circulation) were successfully treated with
the p64MW-HPC. In 30/32 patients (93.75%), aneurysmal perfusion was significantly
reduced immediately post implantation. Follow-up imaging was available for 23
aneurysms. Delayed aneurysm perfusion (OKM A3: 8.7%), reduction in aneurysm size
(OKM B1-3: 26.1%), or sufficient separation from the parent vessel (OKM C1-3 and
D1: 65.2%) was demonstrated at the last available follow-up after a mean of 5.9
months. In two cases, device thrombosis after early discontinuation of DAPT occurred.
One delayed rupture caused a caroticocavernous fistula. The complications were
treated sufficiently and all patients recovered without permanent significant morbidity.
Conclusion: Treatment with the p64MW-HPC is safe and feasible and achieves
good early aneurysm occlusion rates in the proximal intracranial circulation, which are
comparable to those of well-established FDS. Sudden interruption of DAPT in the
early post-interventional phase can cause in-stent thrombosis despite the HPC surface
modification. Deliverability via the 0.021” microcatheter facilitates treatment in challenging
vascular anatomies
Diffusion Weighted Imaging in Gliomas: A Histogram-Based Approach for Tumor Characterization
(1) Background: Astrocytic gliomas present overlapping appearances in conventional MRI. Supplementary techniques are necessary to improve preoperative diagnostics. Quantitative DWI via the computation of apparent diffusion coefficient (ADC) histograms has proven valuable for tumor characterization and prognosis in this regard. Thus, this study aimed to investigate (I) the potential of ADC histogram analysis (HA) for distinguishing low-grade gliomas (LGG) and high-grade gliomas (HGG) and (II) whether those parameters are associated with Ki-67 immunolabelling, the isocitrate-dehydrogenase-1 (IDH1) mutation profile and the methylguanine-DNA-methyl-transferase (MGMT) promoter methylation profile; (2) Methods: The ADC-histograms of 82 gliomas were computed. Statistical analysis was performed to elucidate associations between histogram features and WHO grade, Ki-67 immunolabelling, IDH1 and MGMT profile; (3) Results: Minimum, lower percentiles (10th and 25th), median, modus and entropy of the ADC histogram were significantly lower in HGG. Significant differences between IDH1-mutated and IDH1-wildtype gliomas were revealed for maximum, lower percentiles, modus, standard deviation (SD), entropy and skewness. No differences were found concerning the MGMT status. Significant correlations with Ki-67 immunolabelling were demonstrated for minimum, maximum, lower percentiles, median, modus, SD and skewness; (4) Conclusions: ADC HA facilitates non-invasive prediction of the WHO grade, tumor-proliferation rate and clinically significant mutations in case of astrocytic gliomas
First Experience of Three Neurovascular Centers With the p64MW-HPC, a Low-Profile Flow Diverter Designed for Proximal Cerebral Vessels With Antithrombotic Coating
Background: In the last decade, flow diversion (FD) has been established as
hemodynamic treatment for cerebral aneurysms arising from proximal and distal cerebral
arteries. However, two significant limitations remain—the need for 0.027” microcatheters
required for delivery of most flow diverting stents (FDS), and long-term dual anti-platelet
therapy (DAPT) in order to prevent FDS-associated thromboembolism, at the cost
of increasing the risk for hemorrhage. This study reports the experience of three
neurovascular centers with the p64MW-HPC, a FDS with anti-thrombotic coating that
is implantable via a 0.021” microcatheter.
Materials and methods: Three neurovascular centers contributed to this retrospective
analysis of patients that had been treated with the p64MW-HPC between March 2020
and March 2021. Clinical data, aneurysm characteristics, and follow-up results, including
procedural and post-procedural complications, were recorded. The hemodynamic effect
was assessed using the O’Kelly–Marotta Scale (OKM).
Results: Thirty-two patients (22 female, mean age 57.1 years) with 33 aneurysms
(27 anterior circulation and six posterior circulation) were successfully treated with
the p64MW-HPC. In 30/32 patients (93.75%), aneurysmal perfusion was significantly
reduced immediately post implantation. Follow-up imaging was available for 23
aneurysms. Delayed aneurysm perfusion (OKM A3: 8.7%), reduction in aneurysm size
(OKM B1-3: 26.1%), or sufficient separation from the parent vessel (OKM C1-3 and
D1: 65.2%) was demonstrated at the last available follow-up after a mean of 5.9
months. In two cases, device thrombosis after early discontinuation of DAPT occurred.
One delayed rupture caused a caroticocavernous fistula. The complications were
treated sufficiently and all patients recovered without permanent significant morbidity.
Conclusion: Treatment with the p64MW-HPC is safe and feasible and achieves
good early aneurysm occlusion rates in the proximal intracranial circulation, which are
comparable to those of well-established FDS. Sudden interruption of DAPT in the
early post-interventional phase can cause in-stent thrombosis despite the HPC surface
modification. Deliverability via the 0.021” microcatheter facilitates treatment in challenging
vascular anatomies
First Experience of Three Neurovascular Centers With the p64MW-HPC, a Low-Profile Flow Diverter Designed for Proximal Cerebral Vessels With Antithrombotic Coating
Background: In the last decade, flow diversion (FD) has been established as
hemodynamic treatment for cerebral aneurysms arising from proximal and distal cerebral
arteries. However, two significant limitations remain—the need for 0.027” microcatheters
required for delivery of most flow diverting stents (FDS), and long-term dual anti-platelet
therapy (DAPT) in order to prevent FDS-associated thromboembolism, at the cost
of increasing the risk for hemorrhage. This study reports the experience of three
neurovascular centers with the p64MW-HPC, a FDS with anti-thrombotic coating that
is implantable via a 0.021” microcatheter.
Materials and methods: Three neurovascular centers contributed to this retrospective
analysis of patients that had been treated with the p64MW-HPC between March 2020
and March 2021. Clinical data, aneurysm characteristics, and follow-up results, including
procedural and post-procedural complications, were recorded. The hemodynamic effect
was assessed using the O’Kelly–Marotta Scale (OKM).
Results: Thirty-two patients (22 female, mean age 57.1 years) with 33 aneurysms
(27 anterior circulation and six posterior circulation) were successfully treated with
the p64MW-HPC. In 30/32 patients (93.75%), aneurysmal perfusion was significantly
reduced immediately post implantation. Follow-up imaging was available for 23
aneurysms. Delayed aneurysm perfusion (OKM A3: 8.7%), reduction in aneurysm size
(OKM B1-3: 26.1%), or sufficient separation from the parent vessel (OKM C1-3 and
D1: 65.2%) was demonstrated at the last available follow-up after a mean of 5.9
months. In two cases, device thrombosis after early discontinuation of DAPT occurred.
One delayed rupture caused a caroticocavernous fistula. The complications were
treated sufficiently and all patients recovered without permanent significant morbidity.
Conclusion: Treatment with the p64MW-HPC is safe and feasible and achieves
good early aneurysm occlusion rates in the proximal intracranial circulation, which are
comparable to those of well-established FDS. Sudden interruption of DAPT in the
early post-interventional phase can cause in-stent thrombosis despite the HPC surface
modification. Deliverability via the 0.021” microcatheter facilitates treatment in challenging
vascular anatomies